Although KRAS inhibitor therapies exist [52,53,54], they have faced challenges due to the difficulty of targeting RAS directly and whether the KRAS mutant cancers retain dependence on KRAS, thus giving rise to a need for combinatorial strategies. This evidence concerns the gene KRAS and cancer.